MediFormatica’s Post

View organization page for MediFormatica, graphic

984 followers

G1 Therapeutics and Pepper Bio Announce Ink Global License Agreement for Lerociclib - HIT Consultant #Global License Agreement: G1 Therapeutics and Pepper Bio have announced a global license agreement for Lerociclib, a promising new drug in the field of oncology. This agreement will allow for the development and commercialization of Lerociclib on a global scale. #Lerociclib Overview: Lerociclib is a novel CDK4/6 inhibitor that has shown promising results in preclinical studies. It has the potential to be a game-changer in the treatment of various types of cancer, including breast cancer and lung cancer. #Benefits of Lerociclib: Lerociclib offers several potential benefits over existing CDK4/6 inhibitors, including increased potency, improved safety profile, and enhanced efficacy ai.mediformatica.com #cancer #clinical #livercancer #clinicaltrials #asia #cancertreatment #drugdiscovery #licensing #oncology #breastcancer #radiation #digitalhealth #healthit #healthtech #healthcaretechnology @MediFormatica (https://buff.ly/3JG8rwH)

G1 Therapeutics and Pepper Bio Announce Ink Global License Agreement for Lerociclib

G1 Therapeutics and Pepper Bio Announce Ink Global License Agreement for Lerociclib

To view or add a comment, sign in

Explore topics